Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan with Chemotherapy in Relapsed/Refractory AML
NCT03616470Phase 3Terminated
- Sponsor
- GlycoMimetics
- Start
- Oct 2018
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Uproleselan Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival at 5 years. Started Oct 2018; status: terminated.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03616470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616470.